PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia
NCT02805205 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 484
Last updated 2016-06-20
Summary
The purpose of this study is to estimate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy.
Conditions
Interventions
- DRUG
-
PEG-rhG-CSF
Sponsors & Collaborators
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-04-30
- Primary Completion
- 2016-02-29
- Completion
- 2016-02-29
More Related Trials
-
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
NCT04554056 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
NCT03618810 ·Status: UNKNOWN
-
The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy
NCT02905916 ·Status: UNKNOWN ·Phase: PHASE4
-
Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
NCT01918241 ·Status: UNKNOWN ·Phase: PHASE2
-
Treatment for Elderly Patients With High Risk Breast Cancer
NCT00117910 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
NCT02005458 ·Status: COMPLETED ·Phase: PHASE2
-
Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
NCT03846414 ·Status: UNKNOWN
-
Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy
NCT06711523 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
NCT01611051 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies
NCT04773327 ·Status: UNKNOWN ·Phase: NA
-
A Phase II Study Comparing Pegylated rhG-CSF(HHPG-19K) and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
NCT02119715 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients
NCT01238562 ·Status: COMPLETED ·Phase: PHASE1
-
Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
NCT00035594 ·Status: COMPLETED ·Phase: PHASE3
-
Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
NCT03251768 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
NCT04466137 ·Status: COMPLETED ·Phase: PHASE3
-
A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors
NCT03798665 ·Status: UNKNOWN
-
Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis
NCT03701841 ·Status: UNKNOWN
-
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer
NCT02725606 ·Status: UNKNOWN ·Phase: PHASE1
-
Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
NCT02685111 ·Status: TERMINATED ·Phase: PHASE2
-
Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor
NCT07096479 ·Status: RECRUITING
-
Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma
NCT04460508 ·Status: UNKNOWN ·Phase: PHASE2
-
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
NCT02996617 ·Status: UNKNOWN ·Phase: PHASE4
-
Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)
NCT00115414 ·Status: COMPLETED ·Phase: PHASE2
-
Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients
NCT03246009 ·Status: COMPLETED ·Phase: PHASE1
-
Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients
NCT03376503 ·Status: COMPLETED ·Phase: PHASE1